SFX-01: Ph II STEM started

Evgen began the open-label, European Phase II STEM trial to evaluate 300 mg oral SFX-01 twice daily as an add-on therapy to Faslodex fulvestrant, tamoxifen or a third-generation aromatase inhibitor in...